Notes on the HOPE-3 study

Česká verzia

Authors: Vladimír Soška ^1,2
Authors place of work: Oddělení klinické biochemie, ICRC – oddělení kardiovaskulárních chorob FN u sv. Anny v Brně ¹; Katedra laboratorních metod LF MU Brno a II. interní klinika LF MU a FN u sv. Anny v Brně ²
Published in the journal: Vnitř Lék 2016; 62(11): 929-932
Category:

Summary

The study HOPE-3 aimed to determine whether treatment with statin and with antihypertensive drugs (candesartan and hydrochlorothiazide) in routine clinical practice in people without cardiovascular diseases (men aged over 55, women over 65 years) will reduce cardiovascular events. Another objective was to answer whether the effect of the above-mentioned treatment will be the same in different ethnic (anthropometric) populations. All drugs were administered as an “polypills”. The study demonstrated that use of antihypertensive medication in this population does not reduce the incidence of cardiovascular events. In contrast, statin treatment reduced cardiovascular events statistically highly significant (p = 0.002). The effect of treatment was the same for all ethnic groups included to the study (total of 6 continents).

Key words:
antihypertenzive drugs – cardiovascular prevention – dyslipidemia – hypertension – statins

Zdroje

1. Lonn E, Bosch J, Pogue J et al. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants’ Baseline Characteristics. Can J Cardiol 2016; 32(3): 311–318. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cjca.2015.07.001>.

2. Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016. pii: ehw272. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw272>.

3. Lonn EM, Bosch J, Lopez-Jaramillo P et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374(21): 2009–2020. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1600175>.

4. Yusuf S, Bosch J, Dagenais G et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374(21): 2021–2031. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1600176>.

5. Yusuf S, Lonn E, Pais P et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med 2016; 374(21): 2032–2043. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1600177>.

6. Vaverková H, Soška V, Rosolová H et al. Czech Atherosclerosis Society Guidelines for the diagnosis and treatment of dyslipidemias in adults. Vnitř Lék 2007; 53(2): 181–187.